Mumbai, Nov. 13 -- The decline in revenue was primarily due to deferred shipments at the company's CDMO and FDF sites and some key molecule destocking, and timing of certain project starts, especially at NJ Bio. Adjusting for de-stocking the quarter reported growth of 14%YoY.

Profit before tax (PBT) dropped 51.9% YoY to Rs 83.77 crore in Q2 FY26

Adjusted EBITDA for the quarter was Rs 128.9 crore, with Adjusted EBITDA margins of 23.2%, reflecting the lower volumes, upfront investments in employee costs and certain transition and remediation costs.

On half-yearly basis, the company's consolidated net profit tumbled 42.5% to Rs 122.96 crore despite of 1.2% increase in revenue from operations to Rs 1,104.88 crore in H1 FY26 over H1 FY25. ...